We transcribed and analyzed this morning’s Moberg Pharma (MOB.ST) conference call negative update on the MOB-015 nail fungus  trial results that sent the stock, as well as Canadian licensing partner (for nail fungus product) and GeoInvesting-covered stock, Cipher Pharmaceuticals (OTC:CPHRF) (TSX:CPH), plummeting in early morning trading.

Our detailed breakdown was published this morning at our Premium Portal. What are the implications for where CPHRF’s stock price might be heading next?

We parse the key highlights and have published the conference call transcript, not yet available on Moberg’s site or Seeking Alpha.

Premium members can view our exclusive coverage here.

Subscribe to get this kind of exclusive information before the rest of the market.